Compare Moderna, Inc. (MRNA) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Wendys Co — how do they compare? Moderna, Inc. trades at $219.97 (market cap $78.65B), while Wendys Co trades at $6.16 (market cap $1.19B). The key difference: Moderna, Inc. is far larger — about 66.1× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Wendys Co for 77 Days on average.
| MRNA | WEN | |
|---|---|---|
Market Cap | $78.65B | $1.19B |
Volume | 37,373,437 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $9.33 |
52-Week Low | $22.36 | $6.10 |
Typical Hold Time | 59 Days | 77 Days |
Enterprise Value | $74.80B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Wendy's (WEN) trades at $6.16, down 71% over five years, with a bearish technical signal and recent price near multi-year lows. The company faces declining same-store sales, a major franchisee bankruptcy (Meritage Hospitality, September 2026), and net income margin compression from 7.58% in 2025 to 5.72% in 2026. Valuation appears low with a P/E of 9.45 and P/S of 0.54, but high debt and operational challenges weigh on sentiment. Recent earnings beats provide some positive momentum, but competitive pressures persist.
The outlook remains cautious due to franchisee instability and sales declines. Investment opportunity lies in potential turnaround under new CEO Bob Wright and cheap valuation, but risks include further store closures, debt burden, and intense burger chain competition. Analyst consensus is mixed with a $7.58 price target, but 65% hold ratings reflect uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
